Form 4: Atossa Therapeutics CEO Granted 65,000 RSUs

Atossa Therapeutics' President & CEO, Steven C. Quay, was granted 65,000 restricted stock units, vesting over three years.

Summary

• Steven C. Quay, President & CEO of Atossa Therapeutics, Inc., received a grant of 65,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs will vest in three equal annual installments on the first three anniversaries of March 26, 2026.
• Following this transaction, Steven C. Quay directly beneficially owns 88,038 shares of Common Stock.
• He also indirectly beneficially owns 1,483 shares through Ensisheim Partners, LLC, which he co-owns with Dr. Shu-Chih Chen.
• The number of securities reported has been adjusted to reflect a one-for-fifteen reverse stock split effected on February 2, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this RSU grant as a positive for aligning executive incentives with long-term company performance, though the prior reverse stock split might suggest past share price challenges.

Positives

• The grant of 65,000 Restricted Stock Units (RSUs) to the President & CEO aligns management's interests with long-term shareholder value.
• The vesting schedule over three years encourages long-term commitment and performance from executive leadership.

Future Outlook

The RSUs are scheduled to vest in three equal annual installments on the first three anniversaries of March 26, 2026, indicating a future commitment period for the CEO and aligning his incentives with the company's long-term performance.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants is a common practice to align management incentives with shareholder interests, particularly in biotechnology companies like Atossa Therapeutics, where long-term development cycles are prevalent. This grant reinforces the CEO's vested interest in the company's future success.

Related Party Transactions

• Indirect beneficial ownership of 1,483 shares through Ensisheim Partners, LLC, which is wholly owned by the Reporting Person and Dr. Shu-Chih Chen, with shared voting and investment power. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: Potential for increased alignment of the CEO's interests with long-term shareholder value due to the equity grant and its vesting schedule.

Next Steps

• Vesting of RSUs in three equal annual installments on the first three anniversaries of March 26, 2026.

Key Dates

Recommendation

The grant of restricted stock units to the CEO is a standard practice for executive compensation, aligning management's long-term interests with the company's performance. However, the recent reverse stock split indicates potential past share price weakness, suggesting a 'hold' recommendation until further operational and financial performance details are available.

Keywords

Atossa Therapeutics, ATOS, Steven C. Quay, Restricted Stock Units, RSU grant, insider transaction, Form 4, executive compensation, reverse stock split